TY - JOUR
T1 - New treatments and strategies in acute myeloid leukemia
AU - Ravandi, Farhad
PY - 2011/6
Y1 - 2011/6
N2 - Despite considerable progress in the treatment of acute myeloid leukemia in the past several decades, the prognosis of the majority of patients with this disease remains guarded. Advances in supportive care and better characterization of disease subsets through cytogenetics and molecular analysis have led to significant success in treating specific subsets of patients, such as those with acute promyelocytic leukemia and core binding factor leukemias, particularly among the younger patients who are able to better tolerate the effects of cytotoxic chemotherapy. However, overall, only about 40% of younger patients and <10% of older patients with this disease are alive at 5 years. Current research is focusing on the identification of new cellular targets amenable to specific inhibitors, designing the best strategies for combining these novel agents with traditional chemotherapy regimens, and determining prognostic indicators that may allow us to better stratify therapy.
AB - Despite considerable progress in the treatment of acute myeloid leukemia in the past several decades, the prognosis of the majority of patients with this disease remains guarded. Advances in supportive care and better characterization of disease subsets through cytogenetics and molecular analysis have led to significant success in treating specific subsets of patients, such as those with acute promyelocytic leukemia and core binding factor leukemias, particularly among the younger patients who are able to better tolerate the effects of cytotoxic chemotherapy. However, overall, only about 40% of younger patients and <10% of older patients with this disease are alive at 5 years. Current research is focusing on the identification of new cellular targets amenable to specific inhibitors, designing the best strategies for combining these novel agents with traditional chemotherapy regimens, and determining prognostic indicators that may allow us to better stratify therapy.
KW - AML
KW - New strategies
KW - Therapy
UR - http://www.scopus.com/inward/record.url?scp=84860549260&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84860549260&partnerID=8YFLogxK
U2 - 10.1016/j.clml.2011.02.004
DO - 10.1016/j.clml.2011.02.004
M3 - Article
C2 - 22035750
AN - SCOPUS:84860549260
SN - 2152-2650
VL - 11
SP - S60-S64
JO - Clinical Lymphoma, Myeloma and Leukemia
JF - Clinical Lymphoma, Myeloma and Leukemia
IS - SUPPL.1
ER -